🚀 VC round data is live in beta, check it out!
TransThera Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for TransThera Sciences and similar public comparables like Sunshine Lake Pharma, Jilin Aodong, Tarsus Pharmaceuticals, Tasly and more.
TransThera Sciences Overview
About TransThera Sciences
TransThera Sciences (Nanjing) Inc is a clinical demand-oriented, registrational clinical stage biopharmaceutical company focusing on discovering and developing inventive small molecule therapies for oncology, inflammatory and cardiometabolic diseases. It has internally discovered and developed one Core Product Tinengotinib (TT-00420) and built a pipeline of five clinical stage product candidates and one preclinical stage product candidate with its fully-integrated in-house R&D system. Its Core Product Tinengotinib is a unique multi-targeted kinase (MTK) inhibitor targeting three key pathways. It is undergoing two pivotal/registrational clinical trials for the treatment of cholangiocarcinoma that has progressed following prior FGFR inhibitor therapy, one being conducted in China.
Founded
2014
HQ
Employees
121
Website
Sectors
Financials (FY)
EV
$3B
TransThera Sciences Financials
TransThera Sciences reported last fiscal year revenue of — and negative EBITDA of ($39M).
In the same fiscal year, TransThera Sciences generated — in gross profit, ($39M) in EBITDA losses, and had net loss of ($40M).
TransThera Sciences P&L
In the most recent fiscal year, TransThera Sciences reported revenue of — and EBITDA of ($39M).
TransThera Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| EBITDA | — | XXX | ($39M) | XXX | XXX | XXX |
| Net Profit | — | XXX | ($40M) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
TransThera Sciences Stock Performance
TransThera Sciences has current market cap of $3B, and enterprise value of $3B.
Market Cap Evolution
TransThera Sciences' stock price is $8.03.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3B | $3B | 0.0% | XXX | XXX | XXX | $-0.10 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTransThera Sciences Valuation Multiples
TransThera Sciences trades at (79.8x) EV/EBITDA.
TransThera Sciences Financial Valuation Multiples
As of March 21, 2026, TransThera Sciences has market cap of $3B and EV of $3B.
Equity research analysts estimate TransThera Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
TransThera Sciences has a P/E ratio of (80.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV (current) | $3B | XXX | $3B | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (79.8x) | XXX | XXX | XXX |
| EV/EBIT | — | XXX | (79.3x) | XXX | XXX | XXX |
| P/E | — | XXX | (80.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (78.6x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TransThera Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
TransThera Sciences Margins & Growth Rates
TransThera Sciences' revenue in the last fiscal year declined by (100%).
TransThera Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (20%) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
TransThera Sciences Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sunshine Lake Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Jilin Aodong | XXX | XXX | XXX | XXX | XXX | XXX |
| Tarsus Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| Tasly | XXX | XXX | XXX | XXX | XXX | XXX |
| Spyre Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TransThera Sciences M&A Activity
TransThera Sciences acquired XXX companies to date.
Last acquisition by TransThera Sciences was on XXXXXXXX, XXXXX. TransThera Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by TransThera Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialTransThera Sciences Investment Activity
TransThera Sciences invested in XXX companies to date.
TransThera Sciences made its latest investment on XXXXXXXX, XXXXX. TransThera Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by TransThera Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TransThera Sciences
| When was TransThera Sciences founded? | TransThera Sciences was founded in 2014. |
| Where is TransThera Sciences headquartered? | TransThera Sciences is headquartered in China. |
| How many employees does TransThera Sciences have? | As of today, TransThera Sciences has over 121 employees. |
| Is TransThera Sciences publicly listed? | Yes, TransThera Sciences is a public company listed on HKEX. |
| What is the stock symbol of TransThera Sciences? | TransThera Sciences trades under 02617 ticker. |
| When did TransThera Sciences go public? | TransThera Sciences went public in 2025. |
| Who are competitors of TransThera Sciences? | TransThera Sciences main competitors are Sunshine Lake Pharma, Jilin Aodong, Tarsus Pharmaceuticals, Tasly. |
| What is the current market cap of TransThera Sciences? | TransThera Sciences' current market cap is $3B. |
| Is TransThera Sciences profitable? | No, TransThera Sciences is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.